GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CKD Bio Corp (XKRX:063160) » Definitions » EV-to-FCF

CKD Bio (XKRX:063160) EV-to-FCF : 24.53 (As of Mar. 31, 2025)


View and export this data going back to 2001. Start your Free Trial

What is CKD Bio EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CKD Bio's Enterprise Value is ₩239,158 Mil. CKD Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₩9,749 Mil. Therefore, CKD Bio's EV-to-FCF for today is 24.53.

The historical rank and industry rank for CKD Bio's EV-to-FCF or its related term are showing as below:

XKRX:063160' s EV-to-FCF Range Over the Past 10 Years
Min: -643.54   Med: -6.12   Max: 312.7
Current: 24.71

During the past 13 years, the highest EV-to-FCF of CKD Bio was 312.70. The lowest was -643.54. And the median was -6.12.

XKRX:063160's EV-to-FCF is ranked worse than
52.46% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.45 vs XKRX:063160: 24.71

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-31), CKD Bio's stock price is ₩19890.00. CKD Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩1586.000. Therefore, CKD Bio's PE Ratio (TTM) for today is 12.54.


CKD Bio EV-to-FCF Historical Data

The historical data trend for CKD Bio's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CKD Bio EV-to-FCF Chart

CKD Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.94 -12.61 -24.61 -15.22 25.72

CKD Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -15.22 -25.72 -496.66 23.14 25.72

Competitive Comparison of CKD Bio's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, CKD Bio's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CKD Bio's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CKD Bio's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CKD Bio's EV-to-FCF falls into.


;
;

CKD Bio EV-to-FCF Calculation

CKD Bio's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=239158.472/9748.603
=24.53

CKD Bio's current Enterprise Value is ₩239,158 Mil.
CKD Bio's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩9,749 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CKD Bio  (XKRX:063160) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CKD Bio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=19890.00/1586.000
=12.54

CKD Bio's share price for today is ₩19890.00.
CKD Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1586.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CKD Bio EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CKD Bio's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CKD Bio Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjeongno 3-ga, Seodaemun-gu, Seoul, KOR, 120-756
CKD Bio Corp is engaged in manufacturing and distribution of pharmaceutical materials and medicines. Its products portfolio include antibiotic, lactamase inhibitors, antituberculosis, antidiabetics, immunosuppressants, antihyperlipidemics, intermediates, and probiotics.

CKD Bio Headlines

No Headlines